You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 29, 2024

CLINICAL TRIALS PROFILE FOR VILOXAZINE HYDROCHLORIDE

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for VILOXAZINE HYDROCHLORIDE

Subscribe to access the full database, or Sign Up
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01107496 ↗	A Phase I/IIa, Randomized, Double-Blind Study of the Safety and Efficacy of SPN-812 in Adults With ADHD	Completed	Supernus Pharmaceuticals, Inc.	Phase 1/Phase 2	2010-06-01	This will be a randomized, double-blind, placebo-controlled, parallel group, safety and tolerability study in adults with ADHD. The target subjects are healthy male or female adults aged 18 to 64 years, inclusive, with a diagnosis of ADHD. A total of fifty subjects will be enrolled at approximately 5 sites in the US. Subjects will be randomized (1:1) to one of two treatment groups, SPN-812V or placebo.
NCT02633527 ↗	Efficacy and Safety of SPN-812 (Viloxazine Extended-release Capsule) in Children With ADHD	Completed	Supernus Pharmaceuticals, Inc.	Phase 2	2016-02-01	This was a randomized, double-blind, placebo-controlled, multicenter, 5-arm, parallel-group, dose-ranging study to assess the efficacy and safety of SPN-812 (Viloxazine Extended-release Capsule) in children 6-12 years of age with ADHD.
NCT03247517 ↗	Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Adolescents With ADHD	Completed	Supernus Pharmaceuticals, Inc.	Phase 3	2017-11-02	This study will evaluate the efficacy and safety of low doses of SPN-812 in adolescents 12-17 years of age.
NCT03247530 ↗	Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Children With ADHD	Completed	Supernus Pharmaceuticals, Inc.	Phase 3	2017-10-20	This study will evaluate the efficacy and safety of low doses of SPN-812 in children 6-11 years of age diagnosed with ADHD.
NCT03247543 ↗	Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Children With ADHD	Completed	Supernus Pharmaceuticals, Inc.	Phase 3	2017-10-31	This study will evaluate the efficacy and safety of high doses of SPN 812 in children with ADHD
NCT03247556 ↗	Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Adolescents With ADHD	Completed	Supernus Pharmaceuticals, Inc.	Phase 3	2017-11-20	This study will evaluate the efficacy and safety of high doses of SPN-812 in adolescents (12-17 years old) with ADHD
NCT04016779 ↗	Evaluation of SPN-812 in Adults With Attention-Deficit/Hyperactivity Disorder	Completed	Supernus Pharmaceuticals, Inc.	Phase 3	2019-11-20	This study will evaluate the efficacy and safety of SPN-812, an extended-release formulation of viloxazine, in adults.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for VILOXAZINE HYDROCHLORIDE

Condition Name

Chart
Table

Condition Name for VILOXAZINE HYDROCHLORIDE
Intervention	Trials
ADHD	8
Attention-Deficit/Hyperactivity Disorder	3
Attention-Deficit/Hyperactivity Disorder (ADHD)	1
Obstructive Sleep Apnea	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for VILOXAZINE HYDROCHLORIDE
Intervention	Trials
Attention Deficit Disorder with Hyperactivity	7
Hyperkinesis	3
Sleep Apnea, Obstructive	1
Sleep Apnea Syndromes	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for VILOXAZINE HYDROCHLORIDE

Trials by Country

Map
Table

Trials by Country for VILOXAZINE HYDROCHLORIDE
Location	Trials
United States	64
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for VILOXAZINE HYDROCHLORIDE
Location	Trials
Florida	8
Texas	6
California	6
New York	5
Utah	4
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for VILOXAZINE HYDROCHLORIDE

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for VILOXAZINE HYDROCHLORIDE
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	7
Phase 2	2
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for VILOXAZINE HYDROCHLORIDE
Clinical Trial Phase	Trials
Completed	7
Not yet recruiting	2
Recruiting	1
[disabled in preview]	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for VILOXAZINE HYDROCHLORIDE

Sponsor Name

Chart
Table

Sponsor Name for VILOXAZINE HYDROCHLORIDE
Sponsor	Trials
Supernus Pharmaceuticals, Inc.	11
Apnimed	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for VILOXAZINE HYDROCHLORIDE
Sponsor	Trials
Industry	12
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.